It is time to review concepts on renal involvement in @entity1201 : pre- and post-treatment evaluation of 189 XXXX .

@entity1 @entity8 @entity6371 @entity101 @entity1133 @entity19845 @entity1011 @entity166 @entity5406 @entity1201
BACKGROUND: Functional and morphological @entity8 have been widely described in @entity1201 for decades. Nevertheless few studies have assessed renal function pre- and during treatment after the advent of @entity6371 ( @entity6371 ). METHODS: This is a prospective study involving 189 consecutive @entity1 , with all forms of @entity1201 (Ridley-Jopling scale). Laboratory (serum @entity1133 and @entity1011 , estimated GFR, urinalysis, microalbuminuria, urinary @entity19845 ) and clinical features of @entity8 were evaluated previously and after onset (3 and 8 months later) of @entity6371 . RESULTS: One hundred and eighty-nine @entity1 (M 1.8: F 1; mean age 44        16 years) were included just after diagnosis of @entity1201 and before the introduction of @entity6371 . Mean time until manifestation of symptoms and/or signs of @entity1201 was 29        56 months (25 days-480 months). Microhematuria and microalbuminuria were detected in 7.5% and 9.6% of the cases, respectively. Elevated serum @entity1011 was detected in 34% pre- @entity6371 ; this was statistically more frequent in males, @entity101 and frequent users of non-steroidal anti-inflammatory drugs (NSAID), as well as in @entity1 with @entity5406 , 45.5% by the time of diagnosis, 18% after 3 months and 9% after 8 months of @entity6371 (p   =   0.039). CONCLUSIONS: Our results suggest that functional @entity8 in @entity1201 are currently mild and predominantly of glomerular origin, in opposition to the severe involvement described in the past. This improved outcome of @entity8 secondary to @entity1201 is possibly due to the advent of @entity6371 and effective treatment of episodes of reaction, leading to shorter periods of active @entity166 .
